Niagen Bioscience (NAGE) Receivables - Net (2011 - 2026)

Niagen Bioscience (NAGE) has reported Receivables - Net for 16 consecutive years, with $13.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables - Net rose 84.51% year-over-year to $13.1 million; the TTM figure through Mar 2026 stood at $13.1 million (up 84.51% YoY), while the FY2025 annual figure was $9.7 million, up 25.4% from the prior year.
• Receivables - Net improved to $13.1 million in Q1 2026 per NAGE's latest filing, from $9.7 million in the prior quarter.
• Across five years, Receivables - Net topped out at $13.1 million in Q1 2026 and bottomed at $2.8 million in Q2 2023.
• Historically, Receivables - Net has averaged $6.8 million across 5 years, with a median of $7.1 million in 2024.
• Annual changes were most pronounced in 2022 — Receivables - Net plunged 40.68% — and 2024, when it surged 179.21%.
• Niagen Bioscience's Receivables - Net stood at $3.1 million in 2022, then jumped by 68.84% to $5.2 million in 2023, then soared by 48.41% to $7.8 million in 2024, then climbed by 25.4% to $9.7 million in 2025, then soared by 34.48% to $13.1 million in 2026.
• Business Quant data shows NAGE's Receivables - Net at $13.1 million in Q1 2026, $9.7 million in Q4 2025, and $8.5 million in Q3 2025.